IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tracy A. Willson, et al. Examiner: Zachary C. Howard

Serial No: 09/051,843 **Art Unit:** 1646

Filed: June 29, 1998 **Docket**: 11373

For: A NOVEL HAEMOPOIETIN Date: May 15, 2008

RECEPTOR AND GENETIC SEQUENCES

ENCODING SAME

Confirmation No.: 8485

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

CERTIFICATE OF ELECTRONIC FILING

I hereby certify that this correspondence is being deposited with the United States Patent & Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website.

Dated: May 15, 2008

Xiaochun Zhu

H:\work\536\11373\AMEND\11373.ids4.doc

- 1. Kitamura T. et al., "Expression Cloning of the Human IL-3 Receptor cDNA Reveals a Shared β Subunit for the Human IL-3 and GM-CSF Receptors", *Cell* 66(6): 1165-1174 (1991); and
- 2. Kuwaki T. et al., "Characterization Of Human Interleukin-3 Receptors On A Multi-Factor-Dependent Cell Line", *Biochemical and Biophysical Research Communications* 161(1): 16-22 (1989).

Applicants are submitting copies of Reference Nos. 1-2 as required by 37 C.F.R. §1.98(a)(2)(i) and (ii). The references were cited in an Office Action dated February 15, 2008 received from the European Patent Office. The relevance of these references has been described in the Office Action. A copy of the European Office Action is enclosed.

In compliance with the requirements of 37 C.F.R. §1.98(a)(3), as a concise statement of relevance, as it is presently understood by the individual designated in 35 U.S.C. §1.56(c) most knowledgeable about the content of the information, the undersigned attorney of record submits an Official Action by a foreign examiner in which these references were cited. The relevance to the pending U.S. patent application is that the Office Action issued in a foreign patent application on the same subject matter. However, no independent analysis of the Office Action, the accuracy of the statement of the foreign examiner or the claims of the foreign application under the laws of that country or the United States relative to the subject matter claimed in the present application has been made; the present understanding of the contents thereof by the undersigned being based on the foreign examiner's comments submitted herewith.

The undersigned attorney hereby states that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(c)(1), no fee is required.

Respectfully submitted,

Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C. 400 Garden City Plaza, Suite 300 Garden City, New York 11530 (516) 742-4343 XZ:ab